What top creators are saying about Spruce Biosciences(SPRB)

Maintains a long-term bullish stance with fundamental potential to reach $500 over an extended time horizon as a high-volatility clinical play.

Maintains a strongly bullish outlook with confidence in achieving FDA approval for key pipeline treatments.

Long position following a catalyst event, with high confidence in substantial remaining upside that is not strictly dependent on a single binary outcome.

Pipeline progress is not yet reflected in valuation; holds high long-term conviction with projected 5x to 10x upside potential.

Remaining long despite the trade performing poorly thus far.

Highlighted as a strategic focus in the biotech sector for rare disease drugs.

Maintains a bullish stance despite market fluctuations, citing massive upside potential.

Described as a '10x' opportunity and 'no-brainer'; potential for a $100M Priority Review Voucher (PRV) sale.

The speaker is 'over the moon about' this stock and confirms they are 'still long', indicating a strong bullish conviction.

The host gave a direct buy recommendation, stating 'I think it's still a buy. Spruce is still a buy.'

The speaker is very confident in long-term potential, believing it could be a $1,000 stock. The main risk is initial FDA approval, but ultimate approval is expected. A price below $100 is seen as a buying opportunity.